Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1

Conditions

Vascular Calcification 1Neoplasm Metastasis 1Kidney Diseases 1Hyperparathyroidism 1Chronic Kidney Disease-Mineral and Bone Disorder 1Bone Diseases 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × etelcalcetide hydrochloride × Clear all
NCT03960437 2023-09-21

Parsabiv-MBD

Columbia University

Phase 2 Completed
22 enrolled 14 charts
GenitourinaryHead & Neck

Bone Diseases, Hyperparathyroidism, Kidney Diseases, Neoplasm Metastasis, Chronic Kidney Disease-Mineral and Bone Disorder, Vascular Calcification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡